Friedberg JW, Bordoni R, Patel-Donnelly D, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786-795 No … ← Redox-Induced Aromatic Substitution: A Study on Guanidino-Functionalized Aromatics Genetic medicine gestating for α-thalassemia →